Charles McDermott

Charlie has served as a member of our board of directors since September 2018. From September 2017 to May 2018, he was president and chief business officer of Impact Biomedicines Inc., a privately-held biotechnology company. Prior to that, Charlie served in a number of key leadership roles for of Kala Pharmaceuticals Inc., a publicly-held biopharmaceutical company, including president, chief business officer and interim president. Prior to joining Kala, he was a director and then vice president of business development of Eye Care and Drug Delivery at Allergan plc, a publicly-held global pharmaceutical company, and held a variety of business development positions at deCODE Genetics Inc. (now DGI Resolutions Inc.). Earlier in his career, Charlie was a research scientist in the angiogenesis pharmacology group at Agouron Pharmaceuticals Inc. He currently serves on the board of directors of Primmune Therapeutics Inc., a privately-held biotechnology company. Charlie holds a Master of Business Administration from the University of San Diego, a Master of Arts in Molecular, Cellular and Developmental Biology from the University of California at Santa Barbara, a Bachelor of Science in Biochemistry and Molecular Biology from the University of California Santa Cruz, and a Certificate in Clinical Trial Design and Management from the University of California, San Diego Extension.